Story upgraded mid-call: management spontaneously tops its own prepared version with fresher or bigger facts
The model's full reasoning — Q3 2016 call → NOWe need to determine if management spontaneously upgrades its own story relative to its prepared version during the Q&A or unscripted parts. The prepared remarks are the initial statements by Scott, Chris, Dan. Then Q&A follows. We need to see if any unscripted comments reveal positive developments beyond what was in the prepared remarks. Key points from prepared remarks: - ProTmune: protocol amended to blind, enrollment open at 7 sites, Phase 2 expected Q1 2017. - FATE-NK100: IND filed, clinical testing expected early 2017. - ToleraCyte: pre-IND meeting positive, formulating study. - iPSC platform: planning to submit briefing package to FDA in coming weeks. - Partnership with MSK. Now in Q&A, we need to see if management volunteers any new, concrete, positive developments that are fresher or bigger than the prepared version. First question from Do Kim: asks about intention for Phase 2 data as basis for filing. Scott says they believe it's potential, and they made changes to enable accelerated registration. He mentions they overcame challenges with blinding. This is essentially restating the prepared remarks, not new. Second question from Jim Birchenough: asks about sham control, stratification, etc. Chris answers about stratification and maintaining minimum CMV positive patients. That's a detail but not necessarily an upgrade. Then asks about next steps for ProTmune, Scott mentions haploidentical transplantation as an area of interest. That's a future plan, not a current development. Third question from Mark Breidenbach: asks about blinding necessity, and timing of Phase 1 data. Chris explains bias in GvHD assessment. Scott says they will report Phase 1 data as they clear safety hurdle. That's not new. Then asks about Juno collaboration, Scott says they have active collaboration, delivered data packages. That's not new. Fourth question from Ren Benjamin: asks about statistical significance, Chris explains simulations. Then asks about ProHema, Scott says fundamentally different. Then asks about NK100 study design, Scott says 10-20 patients, updates at conferences. That's not new. Then asks about combination with antibodies, Scott talks about quadrants, but that's general. Then asks about ToleraCyte and iPSC IND timing, Scott says they will submit briefing package in coming weeks, and for ToleraCyte they have clear path. That's restating.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| EGP | EastGroup Properties, Inc. | Q4 2023 | 2024-02-08 | B |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| GS | The Goldman Sachs Group, Inc. | Q2 2023 | 2023-07-19 | C+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| AWRE | Aware, Inc. | Q3 2022 | 2022-10-30 | F |
| CURV | Torrid Holdings Inc. | Q2 2022 | 2022-09-07 | D |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| BHF | Brighthouse Financial, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| KNDI | Kandi Technologies Group, Inc. | Q2 2021 | 2021-08-09 | F |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| TCBI | Texas Capital Bancshares, Inc. | Q2 2021 | 2021-07-21 | F |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| USFD | US Foods Holding Corp. | Q1 2018 | 2018-05-12 | C |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| LII | Lennox International Inc. | Q4 2017 | 2018-02-06 | B+ |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| KHC | The Kraft Heinz Company | Q1 2017 | 2017-05-03 | F |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
| ARKR | Ark Restaurants Corp. | Q1 2016 | 2016-05-13 | B |
| CAL | Caleres, Inc. | Q4 2015 | 2016-03-15 | C+ |
RNW · Q2 2022 → YESThe question is whether management spontaneously upgrades its own story relative to the prepared version during the Q&A. YES The transcript shows management spontaneously upgrading its corporate PPA story in the Q&A. In the prepared remarks, Sumant only referenced the overall corporate PPA market opportunity of at least 25 GW and noted it provides “significant upside” to guidance, without mentioning any signed volume. In the Julien Dumoulin-Smith question-and-answer 30 minutes later, Sumant volunteers the concrete fact that “we’ve already signed up about 100 megawatts worth of PPAs with corporate customers that we have now included in our total number,” and adds that more progress is expected. This is fresher, more specific, and positive relative to the prepared framing, 100 MW being a real, current commitment already folded into the 7 GW operating base.
PFE · Q4 2023 → YESThe question is whether management spontaneously upgrades its own story relative to the prepared remarks during the Q&A, volunteering positive developments that go beyond the prepared presentation, ma...**YES** In the Q&A, management spontaneously volunteers concrete, current positive developments that exceed the prepared remarks in freshness, breadth, and momentum. For example, on Prevnar, Albert directly summarizes that the U.S. adult catch-up opportunity has been exhausted with 96% market share already achieved, pediatric growth is accelerating 4-dose cohort dynamics, and international tenders plus VTC recommendations are delivering immediate traction—facts not framed this way in the opening remarks.
PRIM · Q2 2018 → YESThe question is whether management spontaneously upgrades its own story relative to the prepared remarks with positive developments that are bigger, faster, broader, or more recent. YES In the Q&A, David King spontaneously upgrades the prepared framing of the Willbros T&D awards by volunteering that the three major customers (one announced as $145M MSA, two others leaking out) were customers from the due-diligence meetings who had been hesitant about financial viability but were now actively placing awards — a fresher, broader, and more recent positive development than the prepared remarks’ single mention of “awarded work from some of the largest electrical utilities” in the first two months.